These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31780963)

  • 1. Kundalini Yoga Meditation Versus the Relaxation Response Meditation for Treating Adults With Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
    Shannahoff-Khalsa D; Fernandes RY; Pereira CAB; March JS; Leckman JF; Golshan S; Vieira MSR; Polanczyk GV; Miguel EC; Shavitt RG
    Front Psychiatry; 2019; 10():793. PubMed ID: 31780963
    [No Abstract]   [Full Text] [Related]  

  • 2. Randomized controlled trial of yogic meditation techniques for patients with obsessive-compulsive disorder.
    Shannahoff-Khalsa DS; Ray LE; Levine S; Gallen CC; Schwartz BJ; Sidorowich JJ
    CNS Spectr; 1999 Dec; 4(12):34-47. PubMed ID: 18311106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance of Wellness in Patients With Obsessive-Compulsive Disorder Who Discontinue Medication After Exposure/Response Prevention Augmentation: A Randomized Clinical Trial.
    Foa EB; Simpson HB; Gallagher T; Wheaton MG; Gershkovich M; Schmidt AB; Huppert JD; Imms P; Campeas RB; Cahill S; DiChiara C; Tsao SD; Puliafico A; Chazin D; Asnaani A; Moore K; Tyler J; Steinman SA; Sanches-LaCay A; Capaldi S; Snorrason Í; Turk-Karan E; Vermes D; Kalanthroff E; Pinto A; Hamlett GE; Middleton R; Hahn CG; Xu B; Van Meter PE; Katechis M; Rosenfield D
    JAMA Psychiatry; 2022 Mar; 79(3):193-200. PubMed ID: 35080598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six-month outcomes from a randomized trial augmenting serotonin reuptake inhibitors with exposure and response prevention or risperidone in adults with obsessive-compulsive disorder.
    Foa EB; Simpson HB; Rosenfield D; Liebowitz MR; Cahill SP; Huppert JD; Bender J; McLean CP; Maher MJ; Campeas R; Hahn CG; Imms P; Pinto A; Powers MB; Rodriguez CI; Van Meter PE; Vermes D; Williams MT
    J Clin Psychiatry; 2015 Apr; 76(4):440-6. PubMed ID: 25375780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-blind study of dextroamphetamine versus caffeine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM; Aboujaoude E; Gamel NN
    J Clin Psychiatry; 2009 Nov; 70(11):1530-5. PubMed ID: 19573497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of Rajyoga meditation as an adjunct to first-line treatment in patients with obsessive compulsive disorder.
    Mehta K; Mehta S; Chalana H; Singh H; Thaman RG
    Indian J Psychiatry; 2020; 62(6):684-689. PubMed ID: 33896974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient perspectives: Kundalini yoga meditation techniques for psycho-oncology and as potential therapies for cancer.
    Shannahoff-Khalsa DS
    Integr Cancer Ther; 2005 Mar; 4(1):87-100. PubMed ID: 15695478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A; Ackerman DL; Rosen RM; Vapnik T; Gorbis E; Maidment KM; Saxena S
    J Clin Psychiatry; 2004 Apr; 65(4):565-8. PubMed ID: 15119922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meditation therapy for anxiety disorders.
    Krisanaprakornkit T; Krisanaprakornkit W; Piyavhatkul N; Laopaiboon M
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004998. PubMed ID: 16437509
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
    Simpson HB; Gorfinkle KS; Liebowitz MR
    J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reliability and validity of the Thai version of the Yale-Brown Obsessive Compulsive Scale - Second Edition in clinical samples.
    Hiranyatheb T; Saipanish R; Lotrakul M
    Neuropsychiatr Dis Treat; 2014; 10():471-7. PubMed ID: 24648741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Criterion Validity of the Yale-Brown Obsessive-Compulsive Scale Second Edition for Diagnosis of Obsessive-Compulsive Disorder in Adults.
    Castro-Rodrigues P; Camacho M; Almeida S; Marinho M; Soares C; Barahona-Corrêa JB; Oliveira-Maia AJ
    Front Psychiatry; 2018; 9():431. PubMed ID: 30254588
    [No Abstract]   [Full Text] [Related]  

  • 14. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D; de Geus F; van Megen HJ; Westenberg HG
    J Clin Psychiatry; 2004 Aug; 65(8):1040-8. PubMed ID: 15323587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hungarian translation of the Dimensional Yale-Brown Obsessive-Compulsive Scale and our first experiences with the test].
    Harsányi A; Csigó K; Demeter G; Rajnai C; Németh A; Racsmány M
    Psychiatr Hung; 2009; 24(1):18-59. PubMed ID: 19542567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. D-Cycloserine vs Placebo as Adjunct to Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder and Interaction With Antidepressants: A Randomized Clinical Trial.
    Andersson E; Hedman E; Enander J; Radu Djurfeldt D; Ljótsson B; Cervenka S; Isung J; Svanborg C; Mataix-Cols D; Kaldo V; Andersson G; Lindefors N; Rück C
    JAMA Psychiatry; 2015 Jul; 72(7):659-67. PubMed ID: 25970252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial.
    Afshar H; Akuchekian S; Mahaky B; Zarean E
    J Res Med Sci; 2014 Oct; 19(10):976-81. PubMed ID: 25538783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of an interview-only version of the Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS) in treatment-seeking youth with obsessive-compulsive disorder.
    Cervin M; Perrin S; Olsson E; Claesdotter-Knutsson E; Lindvall M
    Psychiatry Res; 2019 Jan; 271():171-177. PubMed ID: 30481695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reliability and validity of the Thai self-report version of the Yale-Brown Obsessive-Compulsive Scale-Second Edition.
    Hiranyatheb T; Saipanish R; Lotrakul M; Prasertchai R; Ketkaew W; Jullagate S; Udomsubpayakul U; Kusalaruk P
    Neuropsychiatr Dis Treat; 2015; 11():2817-24. PubMed ID: 26604766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Further psychometric properties of the Yale-Brown Obsessive Compulsive Scale - Second Edition.
    Wu MS; McGuire JF; Horng B; Storch EA
    Compr Psychiatry; 2016 Apr; 66():96-103. PubMed ID: 26995242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.